Literature DB >> 33388398

Filling the gap between Guidelines and Real World in the cardiovascular approach to the diabetic patients: the need for a call to action.

Francesco Maranta1, Lorenzo Cianfanelli2, Manfredi Rizzo3, Domenico Cianflone4.   

Abstract

Entities:  

Keywords:  Cardiovascular outcome trials; Cardiovascular prevention; Cardiovascular risk; Diabetes mellitus type 2; Glucose-lowering drugs; Therapeutical targets

Year:  2020        PMID： 33388398     DOI： 10.1016/j.ijcard.2020.12.074

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  4 in total

1.  The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.

Authors:  Samuel J P Malkin; Davide Carvalho; Catarina Costa; Vasco Conde; Barnaby Hunt
Journal:  Diabetol Metab Syndr       Date:  2022-02-14       Impact factor: 3.320

2.  Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).

Authors:  Miodrag Janić; Manfredi Rizzo; Andrej Janež; Francesco Cosentino; Anca Pantea Stoian; Mojca Lunder; Mišo Šabović
Journal:  Diabetes Ther       Date:  2022-03-08       Impact factor: 2.945

3.  The Role of Physicians' Digital Tools in Pharmacological Management of Type 2 Diabetes Mellitus.

Authors:  Andrej Janež; Rok Ješe; Martin Haluzík; Manfredi Rizzo
Journal:  Medicina (Kaunas)       Date:  2022-08-06       Impact factor: 2.948

4.  Incretin-based therapies in 2021 - current status and perspectives for the future.

Authors:  Manfredi Rizzo; Michael A Nauck; Christos S Mantzoros
Journal:  Metabolism       Date:  2021-07-29       Impact factor: 8.694
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.